PL378566A1 - Ligandy dla białek wiążących TGF-beta i ich zastosowania - Google Patents

Ligandy dla białek wiążących TGF-beta i ich zastosowania

Info

Publication number: PL378566A1
Authority: PL; Poland
Prior art keywords: tgf; complex; beta binding; ligands; binding proteins
Prior art date: 2003-03-14

Application number

PL378566A

Other languages

English (en)

Inventor

David G. Winkler

John Latham

John Skonier

Diana Shpektor

Trenton Hayes

James Geoghegan

Original Assignee

Celltech R & D, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-14

Filing date

2004-03-12

Publication date

2006-05-02

2004-03-12 Application filed by Celltech R & D, Inc. filed Critical Celltech R & D, Inc.

2006-05-02 Publication of PL378566A1 publication Critical patent/PL378566A1/pl

Links

ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title abstract 4
108091008324 binding proteins Proteins 0.000 title abstract 3
102000014914 Carrier Proteins Human genes 0.000 title 1
239000003446 ligand Substances 0.000 title 1
102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 3
108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 3
102000019307 Sclerostin Human genes 0.000 abstract 2
108050006698 Sclerostin Proteins 0.000 abstract 2
239000005557 antagonist Substances 0.000 abstract 2
102000023732 binding proteins Human genes 0.000 abstract 2
230000018678 bone mineralization Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
102000006533 chordin Human genes 0.000 abstract 1
108010008846 chordin Proteins 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
102000045246 noggin Human genes 0.000 abstract 1
108700007229 noggin Proteins 0.000 abstract 1
238000007423 screening assay Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Physical Education & Sports Medicine (AREA)
Biochemistry (AREA)
Orthopedic Medicine & Surgery (AREA)
Toxicology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Rheumatology (AREA)
Food Science & Technology (AREA)
Endocrinology (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
Microbiology (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Peptides Or Proteins (AREA)

PL378566A 2003-03-14 2004-03-12 Ligandy dla białek wiążących TGF-beta i ich zastosowania PL378566A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US45525303P	2003-03-14	2003-03-14

Publications (1)

Publication Number	Publication Date
PL378566A1 true PL378566A1 (pl)	2006-05-02

Family

ID=33029975

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL04720380T PL1608399T3 (pl)	2003-03-14	2004-03-12	Kompleks sklerostyny i nogginy lub chordyny, oraz czynniki modulujące tworzenie tego kompleksu
PL378566A PL378566A1 (pl)	2003-03-14	2004-03-12	Ligandy dla białek wiążących TGF-beta i ich zastosowania

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL04720380T PL1608399T3 (pl)	2003-03-14	2004-03-12	Kompleks sklerostyny i nogginy lub chordyny, oraz czynniki modulujące tworzenie tego kompleksu

Country Status (15)

Country	Link
US (1)	US7226902B2 (pl)
EP (1)	EP1608399B1 (pl)
JP (1)	JP4660471B2 (pl)
AT (1)	ATE540977T1 (pl)
AU (1)	AU2004222317B2 (pl)
CA (1)	CA2519131C (pl)
CY (1)	CY1112797T1 (pl)
DK (1)	DK1608399T3 (pl)
ES (1)	ES2379689T3 (pl)
MX (1)	MXPA05009805A (pl)
NZ (1)	NZ542587A (pl)
PL (2)	PL1608399T3 (pl)
PT (1)	PT1608399E (pl)
SI (1)	SI1608399T1 (pl)
WO (1)	WO2004082608A2 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2639020T3 (es)	1998-11-27	2017-10-25	Ucb Pharma S.A.	Composiciones y métodos para incrementar la mineralización de la substancia ósea
CN1835974A (zh)	2003-06-16	2006-09-20	细胞技术研究与发展公司	对硬化素特异的抗体和用于增加骨矿化的方法
US8461155B2 (en) *	2003-09-22	2013-06-11	University Of Connecticut	Sclerostin and the inhibition of WNT signaling and bone formation
US8003108B2 (en)	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
US7592429B2 (en) *	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
WO2007028212A1 (en) *	2005-09-08	2007-03-15	Apollo Life Sciences Limited	Noggin and chimeric molecules thereof
US8131480B2 (en)	2006-10-02	2012-03-06	Sea Lane Biotechnologies Llc	Construction of diverse synthetic peptide and polypeptide libraries
WO2008133722A2 (en) *	2006-11-10	2008-11-06	Ucb Pharma S.A.	Anti human sclerostin antibodies
US20100036091A1 (en) *	2006-11-10	2010-02-11	Amgen Inc.	Antibody-based diagnostics and therapeutics
EP2114435A1 (en) *	2007-02-02	2009-11-11	Novartis AG	Modulators of sclerostin binding partners for treating bone-related disorders
CL2008002775A1 (es)	2007-09-17	2008-11-07	Amgen Inc	Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AU2008338464A1 (en) *	2007-12-14	2009-06-25	Amgen Inc.	Method for treating bone fracture with anti-sclerostin antibodies
CA2742871C (en) *	2008-11-13	2018-10-23	Herb Lin	Methods and compositions for regulating iron homeostasis by modulation of bmp-6
KR101163171B1 (ko) *	2009-01-20	2012-07-19	(주)케어젠	노긴?유래 펩타이드 및 그의 용도
SMT202000095T1 (it)	2010-05-14	2020-03-13	Amgen Inc	Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
JP2014509588A (ja)	2011-03-01	2014-04-21	アムジエン・インコーポレーテツド	二特異性結合剤
US9145457B2 (en)	2011-03-25	2015-09-29	Amgen Inc.	Sclerostin antibody crystals and formulations thereof
ES2667554T3 (es)	2011-08-04	2018-05-11	Amgen Inc.	Método para el tratamiento de los defectos de espacio óseo
KR20190120401A (ko)	2011-12-28	2019-10-23	암젠 인크	항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법
JP6770312B2 (ja)	2012-07-05	2020-10-14	ユセベファルマソシエテアノニム	骨疾患の治療
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
MA41142A (fr)	2014-12-12	2017-10-17	Amgen Inc	Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
GB201604124D0 (en)	2016-03-10	2016-04-27	Ucb Biopharma Sprl	Pharmaceutical formulation
US10961305B2 (en)	2016-12-21	2021-03-30	Mereo Biopharma 3 Limited	Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
EP3774879B1 (en)	2018-03-30	2026-01-28	Amgen Inc.	C-terminal antibody variants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5846770A (en) *	1994-11-22	1998-12-08	Genetics Institute, Inc.	DNA molecules encoding human chordin
CA2220912A1 (en)	1995-06-05	1996-12-12	Gregg A. Hastings	Human ccn-like growth factor
US5989909A (en) *	1997-09-26	1999-11-23	Millennium Biotherapeutics, Inc.	Huchordin and uses thereof
WO1998046588A2 (en) *	1997-04-11	1998-10-22	Neorx Corporation	Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6075007A (en) *	1997-07-17	2000-06-13	Regeneron Pharmaceuticals, Inc.	Modified noggin polypeptide and compositions
AU3367899A (en)	1998-03-30	1999-10-18	Dow Agrosciences Llc	Modification of fatty acid composition in plants by expression of an (aspergillus nidulans) delta-9 coa desaturase
ES2639020T3 (es)	1998-11-27	2017-10-25	Ucb Pharma S.A.	Composiciones y métodos para incrementar la mineralización de la substancia ósea
AU4196801A (en) *	2000-03-02	2001-09-12	Amgen Inc	Chordin-like-2 molecules and uses thereof

2004
- 2004-03-12 EP EP04720380A patent/EP1608399B1/en not_active Expired - Lifetime
- 2004-03-12 PL PL04720380T patent/PL1608399T3/pl unknown
- 2004-03-12 AU AU2004222317A patent/AU2004222317B2/en not_active Ceased
- 2004-03-12 NZ NZ542587A patent/NZ542587A/en not_active IP Right Cessation
- 2004-03-12 MX MXPA05009805A patent/MXPA05009805A/es active IP Right Grant
- 2004-03-12 PT PT04720380T patent/PT1608399E/pt unknown
- 2004-03-12 JP JP2006507118A patent/JP4660471B2/ja not_active Expired - Fee Related
- 2004-03-12 US US10/799,162 patent/US7226902B2/en not_active Expired - Fee Related
- 2004-03-12 WO PCT/US2004/007565 patent/WO2004082608A2/en not_active Ceased
- 2004-03-12 PL PL378566A patent/PL378566A1/pl unknown
- 2004-03-12 ES ES04720380T patent/ES2379689T3/es not_active Expired - Lifetime
- 2004-03-12 CA CA2519131A patent/CA2519131C/en not_active Expired - Fee Related
- 2004-03-12 SI SI200431852T patent/SI1608399T1/sl unknown
- 2004-03-12 DK DK04720380.7T patent/DK1608399T3/da active
- 2004-03-12 AT AT04720380T patent/ATE540977T1/de active
2012
- 2012-04-09 CY CY20121100348T patent/CY1112797T1/el unknown

Also Published As

Publication number	Publication date
JP2006522103A (ja)	2006-09-28
SI1608399T1 (sl)	2012-05-31
US20050085418A1 (en)	2005-04-21
PT1608399E (pt)	2012-04-13
US7226902B2 (en)	2007-06-05
AU2004222317A1 (en)	2004-09-30
WO2004082608A3 (en)	2005-01-20
DK1608399T3 (da)	2012-04-02
AU2004222317B2 (en)	2010-08-19
PL1608399T3 (pl)	2012-09-28
NZ542587A (en)	2008-05-30
ES2379689T3 (es)	2012-04-30
ATE540977T1 (de)	2012-01-15
WO2004082608A9 (en)	2005-03-17
EP1608399B1 (en)	2012-01-11
CY1112797T1 (el)	2016-02-10
CA2519131C (en)	2014-07-08
MXPA05009805A (es)	2006-04-18
WO2004082608A2 (en)	2004-09-30
EP1608399A2 (en)	2005-12-28
CA2519131A1 (en)	2004-09-30
JP4660471B2 (ja)	2011-03-30

Publication	Publication Date	Title
WO2004082608A3 (en)	2005-01-20	Ligands for tgf-beta binding proteins and uses thereof
CY1124802T1 (el)	2022-11-25	Δεσμευτικοι παραγοντες σκληροστινης
MEP3108A (xx)	2010-02-10	Kompozicije i postupci za povećanje mineralizacije kostiju
MEP2808A (xx)	2010-02-10	Antitijela specifična za sklerositin i metode za povećanje mineralizacije kostiju
MY174493A (en)	2020-04-23	Binding agents
MX2007008017A (es)	2007-09-12	Polipeptidos que se ligan a br3 y usos de los mismos.
EA200801621A1 (ru)	2008-12-30	Антитела, направленные на her-3, и их применение
EA200700847A1 (ru)	2007-10-26	Материалы, связывающие прионные белки, и способы их применения
WO2007133623A3 (en)	2008-03-13	Peptide diagnostic agent for lyme disease
TW200745159A (en)	2007-12-16	IL-6 binding proteins
WO2006087163A3 (en)	2007-04-19	Novel in vitro methods for studying receptors recognizing volatile compounds
EA200800205A1 (ru)	2008-08-29	Кальций-пептидный компонент
WO2003060067A3 (en)	2004-07-29	P85-alpha nucleic acids, polypeptides and related methods
WO2006078431A3 (en)	2006-10-12	Compositions and methods related to modified retroviral vectors for restricted, site specific integration
WO2006008266A3 (en)	2006-08-03	Factor xi-binding proteins
HK1151803B (en)	2015-08-28	Sclerostin binding agents
WO2004070347A3 (en)	2004-12-16	Screening for modulators of fat storage
TW200718711A (en)	2007-05-16	Polypeptides that bind BR3 and uses thereof
EP1496945A4 (en)	2006-11-08	Mycoplasma POLYPEPTIDES
UA115859C2 (uk)	2018-01-10	Розчинний поліпептид, який зв'язує активін а, та композиція, що його містить
WO2007050554A3 (en)	2009-04-30	Methods for identifying compounds that modulate phb domain protein activity and compositions thereof
WO2005040208A3 (en)	2005-10-20	Peptides derived from heat shock proteins binding toll-like receptors 2 and 4 and their use
SE0401166D0 (sv)	2004-05-03	Method for protein protection